MILabs
MILabs B.V. designs and sells ultra-high-resolution preclinical and clinical molecular imaging systems (SPECT, PET, CT, Optical) based on proprietary multi-pinhole collimator technology, serving academic research institutions, pharmaceutical companies, and nuclear medicine departments worldwide as a subsidiary of Rigaku Group.
- Company typePrivate
- Founded2006
- HeadquartersUtrecht, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MILabs does
MILabs B.V., headquartered in Houten, Netherlands, is a privately held developer and manufacturer of ultra-high resolution preclinical and clinical molecular imaging systems. Founded in 2006 as a spin-off from the University Medical Centre Utrecht by Professor Frederik Beekman, the company designs integrated platforms combining SPECT, PET, CT, and Optical imaging modalities on a single scalable workflow. Its core proprietary technologies include clustered multi-pinhole collimators optimized for up to 511 keV photon energies, the VECTor platform (the world's first true simultaneous in vivo SPECT and PET system with sub-millimeter resolution), Confocal/Spectral PET for multi-isotope imaging, and the Super Cluster Collimator for theranostic radionuclides such as Ac-225 and At-211. MILabs also offers the G-SPECT clinical system for human imaging, extending its technology base into diagnostic clinical applications.
The company sells high-value capital equipment primarily to academic research institutions (e.g., Beckman Institute, Mayo Clinic, Duke, Purdue, UPENN, VUB) and pharmaceutical/biotechnology firms, with secondary demand from nuclear medicine departments and CROs. Revenue is generated through hardware sales, system upgrades and accessories, professional service and support contracts, and licensing of patented imaging technologies, all conducted via a quote-based sales process. Distribution combines direct enterprise sales with regional channel partners (e.g., HongKong Meilin Group in China, Mid-Atlantic Imaging Services in the Americas) and co-development relationships (TU Delft, SkyScan, UPENN, RS2D). Since August 2021, MILabs has operated as a subsidiary of Rigaku Group (Tokyo, Japan), continuing to develop advanced preclinical imaging systems under founder-led scientific leadership.
MILabs firmographics
Firmographics- Name
- MILabs
- Legal name
- MILabs B.V.
- Website
- https://milabs.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MILabs B.V. designs and sells ultra-high-resolution preclinical and clinical molecular imaging systems (SPECT, PET, CT, Optical) based on proprietary multi-pinhole collimator technology, serving academic research institutions, pharmaceutical companies, and nuclear medicine departments worldwide as a subsidiary of Rigaku Group.
- Ownership category
- akta.pro rank
MILabs industry classification
Industry- Product category
- Preclinical Molecular Imaging Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)
- akta.pro secondary industries
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where MILabs is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
MILabs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Preclinical Imaging Systems Sales: MILabs generates primary revenue from selling high-end preclinical molecular imaging systems (SPECT, PET, CT, Optical) to research institutions and pharmaceutical companies. Systems are sold as integrated platforms with various modality configurations.
- System Upgrades and Accessories: Revenue from upgrading existing systems with new collimators (e.g., VECTor upgrade for U-SPECT-II), accessories, and application-specific configurations.
- Service and Support: Installation, training, application support, and ongoing service maintenance for installed systems through direct staff and regional service partners.
- Technology Licensing: Licensing of proprietary imaging technologies and patented collimator designs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom-configured preclinical imaging systems |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
MILabs product offering
Product offeringCore offering
MILabs designs, manufactures, and sells high-end preclinical and clinical molecular imaging systems for biomedical research. Its portfolio integrates SPECT, PET, CT, and Optical modalities on a single scalable platform, using patented multi-pinhole collimator technology to deliver sub-half-millimeter spatial resolution. Core offerings include U-SPECT, VECTor (simultaneous SPECT/PET), U-PET/CT, Optical imaging, integrated micro-CT, and the G-SPECT clinical system, with specialized collimators such as the Super Cluster Collimator for theranostic radionuclides.
Product overview
MILabs is a preclinical and clinical molecular imaging company offering a comprehensive portfolio of imaging systems. The core product line includes U-SPECT (ultra-high resolution SPECT), VECTor (simultaneous SPECT/PET), U-PET (high-resolution PET with Spectral PET capability), and integrated CT systems. Products range from bench-top mini systems to fully integrated multi-modality platforms combining SPECT/PET/CT and MRI. The portfolio includes specialized collimators (Super Cluster Collimator for theranostics), and extends into clinical imaging with G-SPECT for human SPECT applications. MILabs was acquired by Rigaku Group in August 2021 and continues to develop advanced imaging technologies.
Differentiator
Problem solved
Functional benefit
Products and services
- VECTor/CT Versatile Emission Computed Tomography system combining simultaneous SPECT and PET imaging with integrated CT for preclinical research; the world's first true simultaneous in vivo SPECT/PET preclinical imaging device delivering sub-mm resolution for both modalities.
- U-SPECT Ultra-high resolution Single Photon Emission Computed Tomographer providing the highest resolution SPECT imaging available (down to 0.25mm isotropic uniformly over the field of view) with patented focused multi-pinhole cylindrical collimators for preclinical research.
- U-SPECT/CT Integrated U-SPECT system combined with high-throughput, low-dose micro-CT for fusion of anatomical images with functional SPECT, ensuring high precision data analysis in preclinical research.
- U-CT High-resolution micro-CT subsystem for anatomical imaging, available at multiple resolution levels with fast scan times and low-dose performance for molecular imaging applications.
- Optical Imaging Optical imaging module including 3D and 4D capabilities for molecular imaging applications. Available as standalone 2D optical imaging or hybrid Optical/CT imaging system with Duet Optical docking station.
- VECTor OI/CT Hybrid Optical Imaging with in-line X-ray CT system featuring unique Duet Optical docking station for both high-throughput 2D optical imaging and CT-guided 3D optical tomography of deep tissue.
- U-PET/CT High-resolution PET system with Confocal PET technology enabling Spectral PET (Color PET) for simultaneous detection of dual isotopes and significantly improved signal-to-noise contrast in preclinical research.
- Super Cluster Collimator (SC) Accessory transforming challenging theranostic radionuclides into quantifiable preclinical insight. Provides ultra-high sensitivity (~17%) while maintaining spatial resolution of approximately 1.1-1.3mm at high gamma energies, enabling simultaneous multi-photopeak detection for Ac-225, At-211 and other low-signal isotopes.
- G-SPECT Clinical SPECT System Clinical SPECT system for human use providing <3mm spatial resolution (compared to typical 8-10mm of existing clinical SPECT) with ultra-fast scanning and no rotating detectors. Designed for brain, kidneys and joint imaging with applications in epilepsy, Parkinson's, and Alzheimer's diagnosis.
- VECTor4 and U-SPECT4 Series New 4-series product line comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT with significant improvements including more compact design, dramatically improved X-Ray CT subsystem with reduced radiation dose, increased resolution and speed.
- PET-SPECT-CT-MRI Platform Comprehensive preclinical imaging platform combining PET, SPECT, CT and MRI modalities. Integrates sub-half-mm SPECT resolution, sub-mm PET resolution, with high-resolution X-ray CT and/or compact cryogen-free 1.5T MRI unit for nanobody and multimodal research.
Quantifiable outcome
- 0.25mm spatial resolution achieved with U-SPECT technology
- +4 more outcomes
Companies that use MILabs
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles4 records
MILabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature7 records
MILabs partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- HongKong Meilin Group Co., Ltd.coreLocal partner in China providing sales, technical, and marketing support for MILabs products in the Chinese market. HongKong Meilin Group is a professional distributor for biological research equipment covering molecular imaging, molecular biology, cytology, and immunology.
- University of PennsylvaniaminorCollaboration between UPENN Physics and Instrumentation Group, MILabs, and TU Delft for adaptive SPECT development. Dr. Scott Metzler's work focuses on high performance SPECT instrumentation and image reconstruction.
- Trace'nTreat Network (Marie Curie ITN)minorMILabs participates in Trace'nTreat network, a Marie Curie Initial Training Network funded with over 2 million euros by the European Commission. Network trains young researchers in nuclear diagnostics and radionuclide therapy across academic and private partners including Erasmus MC, TU Delft, and others.
- SkyScan N.V.coreStrategic partnership with SkyScan N.V. (Kontich, Belgium) to deliver highest resolution CT systems integrated with MILabs U-SPECT and VECTor platforms. Partnership includes compatible animal holders, bed designs, and Click-Over interface software for automatic fusion of CT datasets with functional molecular imaging.
- Mid-Atlantic Imaging ServicescoreStrategic service and support agreement for US and Canada. Mid-Atlantic Imaging Services provides installation and first response service support to MILabs customers, supporting MILabs growth and expansion in the Americas market.
- TU Delft (Delft University of Technology)coreAcademic partnership with TU Delft for development of combined PET/SPECT imaging technology leading to VECTor product. Prof. Freek Beekman, founder of MILabs, is professor at TU Delft and previously led development of U-SPECT at the university. Joint research collaboration continues for SPECT protocol optimization and technology development.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
MILabs competitors and assessment
Company assessmentDirect peers
- Bruker: Bruker's Molecular Imaging business offers preclinical PET, SPECT, CT, MRI and optical imaging systems (e.g., BioSpec, Albira, SkyScan); directly competes with MILabs in the preclinical molecular imaging market across similar modalities and customers.
- Mediso Medical Imaging Systems: Mediso manufactures preclinical SPECT, PET, CT, and optical imaging systems (nanoScan, MultiScan), directly competing with MILabs for academic and pharma research customers in the small-animal imaging space.
- MR Solutions: MR Solutions specializes in preclinical cryogen-free MRI systems and multi-modality platforms, with overlapping applications to MILabs' integrated PET-SPECT-CT-MRI preclinical offerings for biomedical research customers.
- Trifoil Imaging: Trifoil Imaging (previously Gamma Medica) offers preclinical SPECT, PET and CT platforms (e.g., Triumph), directly competing with MILabs in the nuclear imaging preclinical research segment.
Broad incumbents
- Revvity: Revvity (formerly PerkinElmer Life Sciences) sells IVIS optical, FMT, and broader preclinical imaging solutions as part of a larger life sciences portfolio; competes with MILabs for animal research lab budgets in pharma and academia.
- Sedecal: Sedecal manufactures preclinical and clinical imaging hardware including SPECT and CT, with overlapping OEM-style imaging components used in small-animal research; part of a broader medical imaging portfolio.
- GE Healthcare: GE Healthcare is a broad incumbent in medical imaging with product adjacencies in clinical SPECT/PET/CT; while primarily clinical, its portfolio and scale shape the procurement reference frame for translational imaging customers evaluating MILabs systems.
Emerging players
- Molecubes: Molecubes is a Belgian emerging player offering preclinical PET, SPECT, CT and optical systems (e.g., β-CUBE, γ-CUBE), targeting similar academic and translational research customers with compact benchtop configurations.
- Aspect Imaging: Aspect Imaging develops preclinical MRI systems and multi-modality platforms; competes with MILabs for translational imaging customers and recently expanded into integrated preclinical imaging workflows.
- Cubresa: Cubresa develops preclinical PET imaging inserts and portable PET systems for brain and translational research; an emerging niche player with overlapping translational imaging applications to MILabs' PET/SPECT preclinical offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
MILabs social profiles
Digital presenceMILabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
MILabs leadership team
Management profileNumber of profiles
Profiles3 records
MILabs funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MILabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MILabs
What does MILabs do?
MILabs designs, manufactures, and sells high-end preclinical and clinical molecular imaging systems for biomedical research. Its portfolio integrates SPECT, PET, CT, and Optical modalities on a single scalable platform, using patented multi-pinhole collimator technology to deliver sub-half-millimeter spatial resolution. Core offerings include U-SPECT, VECTor (simultaneous SPECT/PET), U-PET/CT, Optical imaging, integrated micro-CT, and the G-SPECT clinical system, with specialized collimators such as the Super Cluster Collimator for theranostic radionuclides.
Is MILabs a public or private company?
MILabs is a private company. It is classified as corporate owned and is currently operating.
When was MILabs founded?
MILabs was founded in 2006. It employs 11 to 50 people.
Where is MILabs based?
MILabs is headquartered in Utrecht, Netherlands, in the Europe region.
How does MILabs make money?
Four revenue lines are on record. Preclinical Imaging Systems Sales are the primary driver. The others are system Upgrades and Accessories, service and Support and technology Licensing.
Who are MILabs's main competitors?
Direct peers on record are Bruker, Mediso Medical Imaging Systems, MR Solutions and Trifoil Imaging. Broad incumbents are Revvity, Sedecal and GE Healthcare. Emerging players are Molecubes, Aspect Imaging and Cubresa.
Does MILabs have an API?
No public API is recorded for MILabs.
What industry is MILabs in?
MILabs's product category is Preclinical Molecular Imaging Systems. Its primary akta.pro industry code is HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 334516 and its SIC code is 3826.